Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Odor-No-More | 4.4 | 1.4 | 1.5 | 1.1 | 0.5 | | | |
| BioLargo Engineering, Science & Technologies, LLC | 1.9 | 1.6 | 1.0 | 0.9 | 0.0 | | | |
| BioLargo Water | 0.0 | 0.0 | | | | | | |
| Total revenues [+] | 5.9 | 2.5 | 1.9 | 1.4 | 0.5 | 0.3 | 0.1 | -0.2 |
| Royalties | | | | | | 0.1 | | |
| Products | | | | | | 0.2 | 0.1 | 0.1 |
| Grants | | | | | | 0.2 | 0.1 | |
| Net interest income | | | | | | -3.1 | -1.0 | -0.3 |
| Revenue growth [+] | 132.5% | | 36.4% | 164.3% | 83.6% | 120.3% | -153.9% | -240.9% |
| Odor-No-More | 208.2% | | 29.9% | 122.8% | | | | |
| BioLargo Engineering, Science & Technologies, LLC | 18.8% | | 15.8% | 7091.7% | | | | |
| BioLargo Water | -91.7% | | | | | | | |
| Clyra Segment | -59.7% | | | | | | | |
| Cost of goods sold | 3.0 | 1.4 | 0.9 | 0.7 | 0.0 | 0.1 | 0.1 | 0.1 |
| Gross profit | 2.9 | 1.1 | 0.9 | 0.6 | 0.5 | 0.2 | 0.1 | -0.3 |
| Gross margin | 48.6% | 43.6% | 49.2% | 45.5% | 100.0% | 62.3% | 51.4% | 123.7% |
| Selling, general and administrative | 6.7 | 6.2 | 6.1 | 5.3 | 4.4 | 3.7 | 3.6 | 2.8 |
| Research and development | 1.3 | 1.4 | 1.5 | 1.7 | 1.6 | 1.4 | 0.7 | 0.6 |
| Other operating expenses | | | | | 0.3 | | | -0.3 |
| EBITDA [+] | -5.1 | -6.4 | -6.6 | -6.4 | -5.9 | -4.9 | -4.2 | -3.4 |
| EBITDA growth | -19.8% | | 4.2% | 8.5% | 19.3% | 17.9% | 23.4% | 29.6% |
| EBITDA margin | -87.5% | -253.5% | -356.3% | -466.4% | -1136.8% | -1749.9% | -3268.9% | 1428.7% |
| Depreciation | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | | |
| EBITA | -5.2 | -6.4 | -6.7 | -6.4 | -5.9 | -4.9 | -4.2 | -3.4 |
| EBITA margin | -88.3% | -254.3% | -359.8% | -470.1% | -1142.6% | -1751.6% | -3268.9% | 1428.7% |
| Amortization of intangibles | | | | | | 0.0 | 0.0 | 0.0 |
| EBIT [+] | -5.2 | -6.4 | -6.7 | -6.4 | -5.9 | -4.9 | -4.2 | -3.4 |
| EBIT growth | -19.3% | | 4.4% | 8.8% | 19.5% | 18.0% | 23.3% | 29.5% |
| EBIT margin | -88.3% | -254.3% | -359.8% | -470.1% | -1142.6% | -1755.5% | -3277.5% | 1433.4% |
| Non-recurring items [+] | 0.2 | 0.3 | | | | | | |
| Asset impairment | 0.2 | 0.3 | | | | | | |
| Interest expense | 0.1 | 0.2 | 4.0 | 3.5 | 3.9 | | | |
| Interest expense | 0.1 | 0.2 | 4.0 | 3.5 | 3.9 | 3.1 | 1.0 | 0.3 |
| Other income (expense), net [+] | 0.3 | 0.1 | -0.7 | -0.8 | 0.2 | 0.0 | 0.1 | |
| Gain (loss) on debt retirement | | | -1.0 | -0.7 | | | | |
| Change in fair value of warrants | | | | | | -0.2 | | |
| Other | 0.3 | -0.1 | -4.7 | -4.3 | -3.7 | -3.1 | | |
| Pre-tax income | -5.1 | -6.9 | -11.4 | -10.7 | -9.5 | -8.1 | -5.1 | -3.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Minority interest | -0.7 | 0.2 | -0.8 | -0.5 | -0.4 | -0.2 | 0.0 | 0.0 |
| Net income | -4.5 | -7.1 | -10.7 | -10.2 | -9.1 | -7.8 | -5.1 | -3.7 |
| Net margin | -76.0% | -279.7% | -574.4% | -749.3% | -1767.1% | -2788.9% | -3962.9% | 1560.4% |
| |
| Basic EPS [+] | ($0.02) | ($0.03) | ($0.07) | ($0.08) | ($0.09) | ($0.09) | ($0.06) | ($0.05) |
| Growth | -41.8% | | -16.1% | -9.1% | 3.4% | 48.3% | 30.3% | 33.1% |
| Diluted EPS [+] | ($0.02) | ($0.03) | ($0.07) | ($0.08) | ($0.09) | ($0.09) | ($0.06) | ($0.05) |
| Growth | -41.8% | | -16.1% | -9.1% | 3.4% | 48.3% | 30.3% | 33.1% |
| |
| Shares outstanding (basic) [+] | 268.3 | 247.2 | 152.1 | 122.0 | 98.9 | 87.9 | 84.1 | 80.0 |
| Growth | 8.5% | | 24.7% | 23.3% | 12.5% | 4.5% | 5.1% | 9.7% |
| Shares outstanding (diluted) [+] | 268.3 | 247.2 | 152.1 | 122.0 | 98.9 | 87.9 | 84.1 | 80.0 |
| Growth | 8.5% | | 24.7% | 23.3% | 12.5% | 4.5% | 5.1% | 9.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|